Avant Technologies and Ainnova Tech Begin Acquisition Talks Ahead of FDA Pre-Submission Meeting
Avant Technologies (OTCQB: AVAI) and Ainnova Tech have entered acquisition negotiations to strengthen their position in the AI-driven healthcare industry. The companies, which formed Ai-nova Acquisition Corp (AAC) six months ago, are looking to consolidate before their FDA pre-submission meeting in July 2025 regarding clinical trials for the Vision AI platform in diabetic retinopathy detection.
AAC currently holds worldwide licensing rights for Ainnova's technology portfolio, which includes the Vision AI platform and retinal cameras. The proposed merger aims to streamline the advancement of their technology to market and enhance resource utilization. The companies believe consolidating operations will facilitate their FDA interactions and accelerate their entry into the U.S. market.
Avant Technologies (OTCQB: AVAI) e Ainnova Tech hanno avviato trattative di acquisizione per rafforzare la loro posizione nel settore sanitario guidato dall'intelligenza artificiale. Le aziende, che sei mesi fa hanno costituito Ai-nova Acquisition Corp (AAC), intendono consolidarsi prima del meeting di pre-sottomissione alla FDA previsto per luglio 2025, relativo alle sperimentazioni cliniche della piattaforma Vision AI per la rilevazione della retinopatia diabetica.
AAC detiene attualmente i diritti di licenza mondiali per il portafoglio tecnologico di Ainnova, che include la piattaforma Vision AI e le fotocamere retiniche. La fusione proposta punta a semplificare il percorso di commercializzazione della tecnologia e a migliorare l'utilizzo delle risorse. Le aziende ritengono che la consolidazione delle operazioni faciliterà le interazioni con la FDA e accelererà l'ingresso nel mercato statunitense.
Avant Technologies (OTCQB: AVAI) y Ainnova Tech han iniciado negociaciones de adquisición para fortalecer su posición en la industria sanitaria impulsada por inteligencia artificial. Las compañías, que hace seis meses formaron Ai-nova Acquisition Corp (AAC), buscan consolidarse antes de su reunión de pre-sometimiento con la FDA en julio de 2025 respecto a los ensayos clínicos de la plataforma Vision AI para la detección de retinopatía diabética.
AAC actualmente posee los derechos de licencia mundial para el portafolio tecnológico de Ainnova, que incluye la plataforma Vision AI y cámaras retinianas. La fusión propuesta tiene como objetivo agilizar el avance de su tecnología hacia el mercado y mejorar la utilización de recursos. Las empresas creen que consolidar operaciones facilitará sus interacciones con la FDA y acelerará su entrada al mercado estadounidense.
Avant Technologies (OTCQB: AVAI)와 Ainnova Tech가 AI 기반 헬스케어 산업에서 입지를 강화하기 위해 인수 협상을 진행 중입니다. 두 회사는 6개월 전에 Ai-nova Acquisition Corp (AAC)를 설립했으며, 2025년 7월 예정된 당뇨병성 망막병증 탐지를 위한 Vision AI 플랫폼 임상시험 관련 FDA 사전 제출 회의 전에 통합을 모색하고 있습니다.
AAC는 현재 Vision AI 플랫폼과 망막 카메라를 포함한 Ainnova의 기술 포트폴리오에 대한 전 세계 라이선스 권리를 보유하고 있습니다. 제안된 합병은 기술의 시장 진출 가속화와 자원 활용 극대화를 목표로 합니다. 두 회사는 운영 통합이 FDA와의 소통을 원활하게 하고 미국 시장 진입을 앞당길 것으로 기대하고 있습니다.
Avant Technologies (OTCQB : AVAI) et Ainnova Tech ont entamé des négociations d'acquisition afin de renforcer leur position dans le secteur de la santé piloté par l'IA. Les entreprises, qui ont créé Ai-nova Acquisition Corp (AAC) il y a six mois, cherchent à se consolider avant leur réunion de pré-soumission à la FDA en juillet 2025 concernant les essais cliniques de la plateforme Vision AI pour la détection de la rétinopathie diabétique.
AAC détient actuellement les droits de licence mondiaux du portefeuille technologique d'Ainnova, qui comprend la plateforme Vision AI et les caméras rétiniennes. La fusion proposée vise à faciliter l'avancement de leur technologie vers le marché et à optimiser l'utilisation des ressources. Les entreprises estiment que la consolidation des opérations facilitera leurs échanges avec la FDA et accélérera leur entrée sur le marché américain.
Avant Technologies (OTCQB: AVAI) und Ainnova Tech haben Übernahmeverhandlungen aufgenommen, um ihre Position im KI-gesteuerten Gesundheitswesen zu stärken. Die Unternehmen, die vor sechs Monaten Ai-nova Acquisition Corp (AAC) gegründet haben, wollen sich vor ihrem FDA-Vorabtreffen im Juli 2025 bezüglich klinischer Studien für die Vision AI-Plattform zur Erkennung diabetischer Retinopathie konsolidieren.
AAC hält derzeit weltweite Lizenzrechte für das Technologieportfolio von Ainnova, das die Vision AI-Plattform und Netzhautkameras umfasst. Die vorgeschlagene Fusion zielt darauf ab, die Markteinführung der Technologie zu beschleunigen und die Ressourcennutzung zu optimieren. Die Unternehmen sind überzeugt, dass die Konsolidierung der Aktivitäten ihre Interaktionen mit der FDA erleichtern und den Markteintritt in den USA beschleunigen wird.
- Consolidation could streamline FDA approval process and market entry
- Worldwide licensing rights already secured for Ainnova's technology portfolio
- Strategic timing before FDA pre-submission meeting shows proactive planning
- Potential for enhanced resource efficiency and market competitiveness
- Acquisition terms and financial details not disclosed
- FDA approval outcome remains uncertain
- Integration challenges could affect operational efficiency
Six months ago, the two companies formed Ai-nova Acquisition Corp. (AAC) to advance and commercialize Ainnova's technology portfolio, including its Vision AI platform and its versatile retinal cameras. During that time, the two companies completed further due diligence and focused on an opportunity to work together as one company. The Board of Directors and management team of Avant remain fully committed to executing the Company's strategic plan, which is focused on enhancing long-term value. Leadership at Avant expects the negotiations to move forward with an acquisition of Ainnova.
Both Avant and Ainnova agree that the time is now to solidify the relationship and move forward as one entity prior to the Company's pre-submission meeting with the
Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp., said of the negotiations, "We believe bringing the two companies together will offer tremendous value for shareholders, it will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally.
We feel the joint venture has been a success and both companies have worked well together toward a common goal, so we believe that we can be even more successful and use our resources more effectively as one company to further AI in healthcare."
Currently, AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the
Vargas continued, "The success of our interactions with the FDA are crucial to our success in the clinic and eventually the success of marketing our technology portfolio in
Avant will inform its shareholders of any updates at an appropriate time.
About Ainnova Tech, Inc.
Ainnova is a
About Avant Technologies, Inc.
Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements."Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies, Inc.
info@avanttechnologies.com
Video: https://mma.prnewswire.com/media/2684764/Avant_Technologies_Ainnova_Tech.mp4
Logo: https://mma.prnewswire.com/media/2370694/5312964/Avant_Technologies.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-and-ainnova-tech-begin-acquisition-talks-ahead-of-fda-pre-submission-meeting-302452280.html
SOURCE Avant Technologies Inc.
FAQ
What is the purpose of Avant Technologies (AVAI) acquiring Ainnova Tech?
What technologies does Ainnova Tech bring to the AVAI acquisition?
When is AVAI's FDA pre-submission meeting for diabetic retinopathy detection?
What is the current relationship between Avant Technologies and Ainnova Tech?
What market opportunities will the AVAI-Ainnova merger unlock?
